GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Shiller PE Ratio

Northwest Biotherapeutics (LTS:0K95) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Northwest Biotherapeutics Shiller PE Ratio Historical Data

The historical data trend for Northwest Biotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Shiller PE Ratio Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Northwest Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Northwest Biotherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Northwest Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Shiller PE Ratio falls into.



Northwest Biotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Northwest Biotherapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Northwest Biotherapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.016/131.7762*131.7762
=-0.016

Current CPI (Mar. 2024) = 131.7762.

Northwest Biotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.266 100.560 -0.349
201409 -0.215 100.428 -0.282
201412 -0.415 99.070 -0.552
201503 -0.448 99.621 -0.593
201506 -0.565 100.684 -0.739
201509 0.163 100.392 0.214
201512 -0.174 99.792 -0.230
201603 -0.042 100.470 -0.055
201606 -0.113 101.688 -0.146
201609 -0.213 101.861 -0.276
201612 -0.200 101.863 -0.259
201703 -0.065 102.862 -0.083
201706 -0.039 103.349 -0.050
201709 -0.060 104.136 -0.076
201712 -0.075 104.011 -0.095
201803 -0.064 105.290 -0.080
201806 -0.045 106.317 -0.056
201809 0.015 106.507 0.019
201812 0.000 105.998 0.000
201903 -0.030 107.251 -0.037
201906 0.000 108.070 0.000
201909 -0.008 108.329 -0.010
201912 0.008 108.420 0.010
202003 0.003 108.902 0.004
202006 -0.064 108.767 -0.078
202009 -0.201 109.815 -0.241
202012 -0.275 109.897 -0.330
202103 -0.004 111.754 -0.005
202106 -0.007 114.631 -0.008
202109 -0.007 115.734 -0.008
202112 -0.015 117.630 -0.017
202203 -0.008 121.301 -0.009
202206 -0.008 125.017 -0.008
202209 -0.026 125.227 -0.027
202212 -0.016 125.222 -0.017
202303 -0.008 127.348 -0.008
202306 -0.008 128.729 -0.008
202309 -0.016 129.860 -0.016
202312 -0.016 129.419 -0.016
202403 -0.016 131.776 -0.016

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Northwest Biotherapeutics  (LTS:0K95) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Northwest Biotherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (LTS:0K95) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines